Articles related to COMBINATION THERAPY

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.

This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.

The FDA’s recent approval of Pombiliti + Opfolda just expanded treatment options for the rare inherited lysosomal disorder.

The FDA approval of motixafortide in combination with filgrastim offers a new, evidence-based approach to improve stem cell mobilization in multiple myeloma patients undergoing ASCT.

Discover how the FLAURA2 trial’s findings on combination therapy could revolutionize initial treatment plans for NSCLC patients with EGFR mutations. Learn more about the significant extension in progression-free survival and its potential clinical implications.

The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.